Azenta(AZTA.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Azenta
AZTA.US
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates through Sample Management Solutions and Multiomics segments. The Sample Management Solutions segment provides sample management products and services, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services.
803.56 B
AZTA.USMarket value -Rank by Market Cap -/-

Financial Score

19/01/2026 Update
C
Life Sciences Tools and ServicesIndustry
Industry Ranking30/61
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE1.40%C
    • Profit Margin-9.39%D
    • Gross Margin45.52%B
  • Growth ScoreC
    • Revenue YoY3.55%C
    • Net Profit YoY66.18%A
    • Total Assets YoY-1.94%D
    • Net Assets YoY-2.31%D
  • Cash ScoreD
    • Cash Flow Margin-1064.90%E
    • OCF YoY3.55%C
  • Operating ScoreD
    • Turnover0.29D
  • Debt ScoreA
    • Gearing Ratio16.15%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Azenta getting closer to key technical measure

    Azenta shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

    MSN·
    US
    AZTA
    +0.23%
    MSN·
    US
    AZTA
    +0.23%

    A Look At Azenta (AZTA) Valuation After Recent Share Price Momentum And Modest Undervaluation Estimate

    Azenta (AZTA) has gained investor attention with a recent share price of $37.92, reflecting a 23.92% increase over three months, despite a 27.45% decline in one-year total returns. The stock is currently about 15% below the analyst price target and 49% below its intrinsic value estimate of $40.17, indicating modest undervaluation. The analysis suggests a future P/E multiple of 72.17x, driven by expectations of margin expansion and earnings growth, although risks such as delayed orders and softness in sequencing services remain. The article emphasizes the importance of considering multiple investment opportunities.

    Simplywall·
    US
    AZTA
    +0.23%
    Simplywall·
    US
    AZTA
    +0.23%

    IBD rating upgrades: Azenta flashes improved price strength

    A Relative Strength Rating upgrade for Azenta shows improving technical performance. Will it continue?

    MSN·
    US
    AZTA
    +0.23%
    MSN·
    US
    AZTA
    +0.23%

    Azenta Enters Definitive Agreement for the Sale of its B Medical Systems Business to THELEMA S.À R.L. | AZTA Stock News

    Azenta, Inc. has signed a definitive agreement to sell its B Medical Systems business to THELEMA S.À R.L. for $63 million, with the transaction expected to close by March 31, 2026. CEO John Marotta stated that this sale will help simplify the company's portfolio and focus on core capabilities. The proceeds will be used to strengthen the company and enhance shareholder value. William Blair acted as the financial advisor for this transaction.

    StockTitan·
    US
    AZTA
    +0.23%
    StockTitan·
    US
    AZTA
    +0.23%

    Is Azenta’s Buyback and M&A Push Recalibrating the Investment Case For Azenta (AZTA)?

    Azenta, Inc. announced a US$250 million share repurchase program through 2028 and plans for disciplined M&A focused on high-margin, recurring-revenue life sciences assets. Management highlighted 60 potential acquisition targets with strict financial filters. The buyback and M&A push aim to reshape Azenta's medium-term investment narrative, despite risks from softer demand. Azenta projects $684.6 million revenue and $34.5 million earnings by 2028, with a fair value estimate of $39.83, a 16% upside to its current price.

    Simplywall·
    US
    AZTA
    +0.23%
    Simplywall·
    US
    AZTA
    +0.23%
    © 2026 Longbridge｜Disclaimer